AZN241108P69000
- 5.13
- 0.000.00%
AstraZeneca Newsroom
Express News | AstraZeneca's $1.5 billion Singapore factory project has commenced, expected to be operational in 2029, creating over 800 high-skilled jobs.
AstraZeneca's New Cancer Drug Manufacturing Facility to Create 800 Jobs in Singapore
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)
Nektar Releases Promising Phase 2 Results for NKTR-255 in Lymphopenia
Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics
Earnings Preview: AstraZeneca to Report Financial Results Pre-market on November 12
$AstraZeneca(AZN.US)$ is scheduled to release its financial results pre-market on November 12 ET. Earnings PreviewAnalysts estimate $AstraZeneca(AZN.US)$ to post revenue of USD13.08B for 2024Q3, up 13
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Big Movers: GlobalFoundries, Cummins, Celanese, Wynn Resorts, and AstraZeneca
Express News | The pacific health insurance has formed an alliance with pfizer, astrazeneca, and others to provide patients with an integrated solution of "medication + service + insurance".
Express News | Market news: Former and current executives of astrazeneca are also under investigation.
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
AlphaValue/Baader Europe Upgrades AstraZeneca to Buy, Raises PT
US stock mining | AI demand surges! Software giant palantir soared nearly 200% this year, "little nvidia" ALAB surged nearly 40% last night
The election topic ignites hot discussions! The media platform Reddit tracked the election night, surging over 12% overnight, closing at a new high.
AstraZeneca Raised to Hold From Sell by Deutsche Bank
Express News | Astrazeneca: Currently, we do not comment on the ongoing investigation, but will fully cooperate with the Chinese law enforcement authorities if requested.
Daiichi Sankyo/AstraZeneca (AZN.US) received approval in China for the fourth indication of Durvalumab.
Recently, the fourth indication for which the combination development and commercialization of the dequ medical vumab monoclonal antibody developed jointly by Astrazeneca (AZN.US) and Daiichi Sankyo has been approved in China is for the treatment of adults with unresectable or metastatic non-small cell lung cancer with HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy.
AstraZeneca's China Business Under Spotlight Amid Fraud Case
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Sector Update: Health Care Stocks Rise Tuesday Afternoon